BR100 Decreased By (-0%)
BR30 Decreased By (-0.12%)
KSE100 No Change (0%)
KSE30 No Change (0%)
BECO 6.03 Increased By ▲ 0.26 (4.51%)
BML 52.75 Decreased By ▼ -0.25 (-0.47%)
BOP 34.25 Increased By ▲ 0.26 (0.76%)
CNERGY 8.16 Increased By ▲ 0.05 (0.62%)
DCL 12.34 Increased By ▲ 0.14 (1.15%)
FCCL 53.89 Increased By ▲ 1.06 (2.01%)
FCSC 5.22 Increased By ▲ 0.15 (2.96%)
FFL 18.03 Increased By ▲ 0.08 (0.45%)
FNEL 1.30 Increased By ▲ 0.01 (0.78%)
HUMNL 11.00 Increased By ▲ 0.12 (1.1%)
KEL 8.11 Increased By ▲ 0.09 (1.12%)
KOSM 5.38 Decreased By ▼ -0.14 (-2.54%)
MLCF 88.05 Increased By ▲ 1.54 (1.78%)
NBP 186.48 Increased By ▲ 1.32 (0.71%)
PACE 10.72 Increased By ▲ 0.14 (1.32%)
PAEL 39.94 Increased By ▲ 0.52 (1.32%)
PIAHCLA 26.17 Decreased By ▼ -0.05 (-0.19%)
PIBTL 17.32 Increased By ▲ 0.65 (3.9%)
PPL 232.78 Increased By ▲ 4.60 (2.02%)
PRL 34.95 Increased By ▲ 0.27 (0.78%)
PTC 67.56 Increased By ▲ 2.23 (3.41%)
SEARL 90.93 Increased By ▲ 0.80 (0.89%)
SSGC 27.17 Increased By ▲ 0.57 (2.14%)
TELE 8.57 Increased By ▲ 0.29 (3.5%)
THCCL 60.13 Increased By ▲ 1.63 (2.79%)
TPLP 8.76 Increased By ▲ 0.54 (6.57%)
TREET 24.54 Increased By ▲ 0.01 (0.04%)
TRG 71.75 Increased By ▲ 2.04 (2.93%)
WAVES 9.98 Increased By ▲ 0.04 (0.4%)
WTL 1.26 Decreased By ▼ -0.02 (-1.56%)
World

Sudan to receive first batch of Sinopharm vaccines

  • Sudan became the first country in the Middle East and North Africa region to receive vaccine doses through the COVAX facility this month when 828,000 doses of the shot produced by AstraZeneca arrived in the East African country.
Published March 24, 2021 Updated March 24, 2021 09:41pm
By

KHARTOUM: Sudan will receive its first shipment of 250,000 doses of the Chinese Sinopharm COVID-19 vaccine on Friday, state news agency SUNA said on Wednesday.

Sudan became the first country in the Middle East and North Africa region to receive vaccine doses through the COVAX facility this month when 828,000 doses of the shot produced by AstraZeneca arrived in the East African country.

Comments

Comments are closed for this article.